REPRESENTATIVENESS OF THE DABIGATRAN, APIXABAN AND RIVAROXABAN
CLINICAL TRIAL POPULATIONS TO REAL-WORLD ATRIAL FIBRILLATION
PATIENTS IN THE UNITED KINGDOM: A CROSS-SECTIONAL ANALYSIS USING
THE GENERAL PRACTICE RESEARCH DATABASE
REPRESENTATIVENESS OF THE DABIGATRAN, APIXABAN AND RIVAROXABAN
CLINICAL TRIAL POPULATIONS TO REAL-WORLD ATRIAL FIBRILLATION
PATIENTS IN THE UNITED KINGDOM:A CROSS-SECTIONAL ANALYSIS USING THE
GENERAL PRACTICE RESEARCH DATABASE
JOURNALSally Lee,1 Brigitta U MOnz,2 Andreas Clemens,3 Martha
Brueckmann,3 Gregory Y H Lip4
MAPOR, Boehringer Ingelheim Ltd., Bracknell, UKBoehringer
Ingelheim GmbH, Ingelheim, GermanyCD Dev & Med Aff, Boehringer
Ingelheim Pharma GmbH & Co. KG, Ingelheim GermanyUniversity of
Birmingham Centre for Cardiovascular Sciences, City Hospital
Birmingham, Birmingham, UKIntan Solihat Samsudin 1115043
Tutor : dr. Hary Gustian, SpPD, FINASIM
Medicine Faculty Maranatha Christian UniversityInternal Medicine
Department Immanuel HospitalBandung2015BackgroundAtrial
fibrillation (AF) is the most common sustained cardiac arrhythmia,
and is associated with an increased risk of stroke and other
thromboembolic events.Oral anticoagulants form the current standard
of care for patients with AF considered at intermediate to high
risk of stroke, and are effective therapies for stroke
prevention.warfarin was the only available; for now, three novel
oral anticoagulant agents (dabigatran etexilate (later referred to
as dabigatran), apixaban and rivaroxaban)RE-LY (n=18 113)
Dabigatran at dose 150 & 110 mg twice daily was associated
with a lower rate of stroke or systemic embolism. At lower dose
dabigatran significantly reduced major bleeding compared to
warfarin (RR, 95% CI 0.80, 0.70 to 0.93; p=0.003).ARISTOTLE
(n=18201)
Apixaban (5 mg, twice daily) was associated with a lower rate of
stroke or systemic embolism (hazard ratio (HR), 95% CI 0.79, 0.66
to 0.95; p
